Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Limited Availability and Use of Clozapine in State Prisons.

Sheitman BB, Catlett TL, Zarzar TR.

Psychiatr Serv. 2019 Mar 1;70(3):256. doi: 10.1176/appi.ps.201800470. No abstract available.

PMID:
30821210
2.

Clozapine Reduces Self-Injurious Behavior in a State Prison Population.

Zarzar TR, Catlett TL, O'Connell MG, Harrelson BH, Wilson VP, Rashad GN, Morris DB, Williams JB, Peebles SS, Sheitman BB.

J Am Acad Psychiatry Law. 2019 Mar;47(1):61-67. doi: 10.29158/JAAPL.003818-19. Epub 2019 Feb 19.

PMID:
30782606
3.

A Model of Enhanced Primary Care for Patients with Severe Mental Illness.

Perrin J, Reimann B, Capobianco J, Wahrenberger JT, Sheitman BB, Steiner BD.

N C Med J. 2018 Jul-Aug;79(4):240-244. doi: 10.18043/ncm.79.4.240.

4.

Acute Crisis Care for Patients with Mental Health Crises: Initial Assessment of an Innovative Prehospital Alternative Destination Program in North Carolina.

Creed JO, Cyr JM, Owino H, Box SE, Ives-Rublee M, Sheitman BB, Steiner BD, Williams JG, Bachman MW, Cabanas JG, Myers JB, Glickman SW.

Prehosp Emerg Care. 2018 Sep-Oct;22(5):555-564. doi: 10.1080/10903127.2018.1428840. Epub 2018 Feb 7.

PMID:
29412043
5.

Dental Care: A Necessary Component of Integrated Care.

Cordle AL, Sheitman BB, Steiner BD.

Prim Care Companion CNS Disord. 2016 Oct 27;18(5). doi: 10.4088/PCC.15l01929. No abstract available.

6.

A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.

Kelly AC, Sheitman BB, Hamer RM, Rhyne DC, Reed RM, Graham KA, Rau SW, Gilmore JH, Perkins DO, Peebles SS, VanderZwaag CJ, Jarskog LF.

J Clin Psychopharmacol. 2014 Aug;34(4):441-5. doi: 10.1097/JCP.0000000000000159.

PMID:
24943389
7.

Examining the relationship between adjunctive psychotherapy use and antipsychotic persistence and hospitalization.

Wang CC, Maciejewski ML, Rao JK, Sheitman BB, Sleath BL, Farley JF.

Adm Policy Ment Health. 2014 Sep;41(5):598-607. doi: 10.1007/s10488-013-0503-7.

PMID:
23733044
8.

Integrating forensically and civilly committed adult inpatients in a treatment mall program at a state hospital.

Webster SL, Sheitman BB, Barboriak PN, Harmon SH, Paesler BT, Gordon PA, Kelly SY, Geller JL.

Psychiatr Serv. 2009 Feb;60(2):262-5. doi: 10.1176/appi.ps.60.2.262.

PMID:
19176424
9.

Managing treatment resistant violent adolescents: a step forward by substituting seclusion for mechanical restraint?

Larson TC, Sheitman BB, Kraus JE, Mayo J, Leidy L.

Adm Policy Ment Health. 2008 May;35(3):198-203. Epub 2007 Dec 5.

PMID:
18058220
10.

Providing medical care in state psychiatric hospitals.

Saik S, Sheitman BB, Mann S, Stelle WW, Osberg JW 3rd.

N C Med J. 2007 Mar-Apr;68(2):95-8.

PMID:
17566553
11.

Dyskinesias differentiate autistic disorder from catatonia.

Brasic JR, Barnett JY, Will MV, Nadrich RH, Sheitman BB, Ahmad R, Mendonca Mde F, Kaplan D, Brathwaite C.

CNS Spectr. 2000 Dec;5(12):19-22.

PMID:
17545961
12.

Adjunctive transdermal nicotine reduced behavioral agitation in severe dementia.

Carmel H, Sheitman BB.

Am J Geriatr Psychiatry. 2007 May;15(5):449. No abstract available.

PMID:
17463196
13.

Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.

Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA.

J Clin Psychiatry. 2005 Dec;66(12):1564-8.

PMID:
16401158
14.

Implementing a smoking ban in an acute psychiatric admissions unit.

Matthews LS, Diaz B, Bird P, Cook A, Stephenson AE, Kraus JE, Sheitman BB.

J Psychosoc Nurs Ment Health Serv. 2005 Nov;43(11):33-6.

PMID:
16350913
15.

Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.

Müller DJ, De Luca V, Sicard T, King N, Hwang R, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Meltzer HY, Kennedy JL.

Eur Neuropsychopharmacol. 2005 Oct;15(5):525-31. Epub 2005 Apr 14.

PMID:
16139171
16.

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.

Müller DJ, Klempan TA, De Luca V, Sicard T, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Honer WG, Kennedy JL.

Neurosci Lett. 2005 May 6;379(2):81-9. Epub 2005 Jan 26.

PMID:
15823421
17.

Clozapine reduces violent behavior in heterogeneous diagnostic groups.

Kraus JE, Sheitman BB.

J Neuropsychiatry Clin Neurosci. 2005 Winter;17(1):36-44.

PMID:
15746481
18.

Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.

De Luca V, Vincent JB, Müller DJ, Hwang R, Shinkai T, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Kennedy JL.

Pharmacol Res. 2005 Apr;51(4):381-4.

PMID:
15683753
19.

Neurosyphilis in newly admitted psychiatric patients: three case reports.

Saik S, Kraus JE, McDonald A, Mann SG, Sheitman BB.

J Clin Psychiatry. 2004 Jul;65(7):919-21.

PMID:
15291680
20.

Are the negative symptoms of schizophrenia consistent with an autistic spectrum illness?

Sheitman BB, Kraus JE, Bodfish JW, Carmel H.

Schizophr Res. 2004 Jul 1;69(1):119-20. No abstract available.

PMID:
15145477
21.

Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features.

Alamy SS, Jarskog LF, Sheitman BB, Lieberman JA.

Schizophr Res. 2004 Feb 1;66(2-3):183-6.

PMID:
15061252
22.

Secretin for refractory schizophrenia.

Sheitman BB, Knable MB, Jarskog LF, Chakos M, Boyce LH, Early J, Lieberman JA.

Schizophr Res. 2004 Feb 1;66(2-3):177-81.

PMID:
15061251
23.

Characteristics of violent behavior in a large state psychiatric hospital.

Kraus JE, Sheitman BB.

Psychiatr Serv. 2004 Feb;55(2):183-5.

PMID:
14762245
24.

A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.

Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA.

Neuropsychopharmacology. 2004 Jan;29(1):133-45.

25.

Clozapine as a first treatment for schizophrenia.

Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM.

Am J Psychiatry. 2003 Aug;160(8):1514-6.

PMID:
12900316
26.

Ziprasidone alternative for olanzapine-induced hyperglycemia.

Spivak B, Alamy SS, Jarskog LF, Sheitman BB, Lieberman JA.

Am J Psychiatry. 2002 Sep;159(9):1606. No abstract available.

PMID:
12202289
27.

IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness.

Sheitman BB, Murray MG, Snyder JA, Silva S, Goldman R, Chakos M, Volavka J, Lieberman JA.

Schizophr Res. 2000 Dec 15;46(2-3):203-7.

PMID:
11120432
28.

Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization.

Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman JA, Bracha SH, Ali SF.

Mol Psychiatry. 1999 Nov;4(6):512-23. Review.

PMID:
10578232
29.

Olanzapine-induced elevation of plasma triglyceride levels.

Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C.

Am J Psychiatry. 1999 Sep;156(9):1471-2. No abstract available.

PMID:
10484969
30.

An integrated view of pathophysiological models of schizophrenia.

Duncan GE, Sheitman BB, Lieberman JA.

Brain Res Brain Res Rev. 1999 Apr;29(2-3):250-64. Review.

PMID:
10209235
31.

Progressive catatonia.

Brasić JR, Zagzag D, Kowalik S, Prichep L, John ER, Liang HG, Klutchko B, Cancro R, Sheitman BB, Buchsbaum M, Brathwaite C.

Psychol Rep. 1999 Feb;84(1):239-46.

PMID:
10203957
32.

Clinical assessment of adventitious movements.

Brasić JR, Barnett JY, Sheitman BB, Lafargue RT, Ahn SC.

Psychol Rep. 1998 Dec;83(3 Pt 1):739-50.

PMID:
9923147
33.

The natural history and pathophysiology of treatment resistant schizophrenia.

Sheitman BB, Lieberman JA.

J Psychiatr Res. 1998 May-Aug;32(3-4):143-50. Review.

PMID:
9793867
34.

High-dose olanzapine for treatment-refractory schizophrenia.

Sheitman BB, Lindgren JC, Early J, Sved M.

Am J Psychiatry. 1997 Nov;154(11):1626. No abstract available.

PMID:
9356581
35.
36.

Adverse effects of clomipramine.

Brasić JR, Barnett JY, Sheitman BB, Tsaltas MO.

J Am Acad Child Adolesc Psychiatry. 1997 Sep;36(9):1165-6. No abstract available.

PMID:
9291715
37.

The evaluation and treatment of first-episode psychosis.

Sheitman BB, Lee H, Strous R, Lieberman JA.

Schizophr Bull. 1997;23(4):653-61. Review. Erratum in: Schizophr Bull. 2006 Apr;32(2):401. Strauss, R [corrected to Strous, R].

PMID:
9366001
38.

Tardive dyskinesia induced by risperidone?

Woerner MG, Sheitman BB, Lieberman JA, Kane JM.

Am J Psychiatry. 1996 Jun;153(6):843. No abstract available.

PMID:
8633711
39.

Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation.

Brasic JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, Kowalik S, Clark A, Tsaltas MO, Young JG.

Neurology. 1994 Jul;44(7):1309-12.

PMID:
8035936

Supplemental Content

Loading ...
Support Center